PMID- 21505182
OWN - NLM
STAT- MEDLINE
DCOM- 20120105
LR  - 20201226
IS  - 1940-6215 (Electronic)
IS  - 1940-6215 (Linking)
VI  - 4
IP  - 8
DP  - 2011 Aug
TI  - Multiple antigenic peptides of human heparanase elicit a much more potent immune 
      response against tumors.
PG  - 1285-95
LID - 10.1158/1940-6207.CAPR-11-0083 [doi]
AB  - Peptide vaccination for cancer immunotherapy requires an ideal immune response 
      induced by epitope peptides derived from tumor-associated antigens (TAA). 
      Heparanase is broadly expressed in various advanced tumors. Accumulating evidence 
      suggests that heparanase can serve as a universal TAA for tumor immunotherapy. 
      However, due to the low immunogenicity of peptide vaccines, an ideal immune 
      response against tumors usually cannot be elicited in patients. To increase the 
      immunogenicity of peptide vaccines, we designed three 4-branched multiple 
      antigenic peptides (MAP) on the basis of the human leukocyte antigen 
      (HLA)-A2-restricted cytotoxic T lymphocyte (CTL) epitopes of human heparanase 
      that we identified previously as antigen carriers. Our results show that MAP 
      vaccines based on the HLA-A2-restricted CLT epitopes of human heparanase were 
      capable of inducing HLA-A2-restricted and heparanase-specific CTL in vitro and in 
      mice. Moreover, compared with their corresponding linear peptides, heparanase MAP 
      vaccines elicited much stronger lysis of tumor cells by activating CD8(+) T 
      lymphocytes and increasing the releasing of IFN-gamma. However, these 
      heparanase-specific CTLs did not lyse heparanase-expressing autologous 
      lymphocytes and dendritic cells, which confirm the safety of these MAP vaccines. 
      Therefore, our findings indicate that MAP vaccines based on CTL epitopes of human 
      heparanase can be used as potent immunogens for tumor immunotherapy because of 
      advantages such as broad spectrum, high effectiveness, high specificity, and 
      safety.
FAU - Wang, Guo-Zhen
AU  - Wang GZ
AD  - Institute of Gastroenterology, Third Military Medical University, Chongqing 
      400038, China.
FAU - Tang, Xu-Dong
AU  - Tang XD
FAU - Lu, Mu-Han
AU  - Lu MH
FAU - Gao, Jin-Hua
AU  - Gao JH
FAU - Liang, Guang-Ping
AU  - Liang GP
FAU - Li, Ning
AU  - Li N
FAU - Li, Chang-Zhu
AU  - Li CZ
FAU - Wu, Yu-Yun
AU  - Wu YY
FAU - Chen, Ling
AU  - Chen L
FAU - Cao, Ya-Ling
AU  - Cao YL
FAU - Fang, Dian-Chun
AU  - Fang DC
FAU - Yang, Shi-Ming
AU  - Yang SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110419
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Antigens)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (Peptides)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 3.2.1.- (heparanase)
RN  - EC 3.2.1.31 (Glucuronidase)
SB  - IM
MH  - Animals
MH  - Antigens/*chemistry
MH  - Antigens, Neoplasm/chemistry
MH  - Bone Marrow/metabolism
MH  - Cell Line, Tumor
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Epitopes/chemistry
MH  - Glucuronidase/*immunology
MH  - Hep G2 Cells
MH  - Humans
MH  - Immune System
MH  - Immunotherapy/methods
MH  - Interferon-gamma/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasms/*immunology
MH  - Peptides/*chemistry
MH  - T-Lymphocytes, Cytotoxic/cytology
EDAT- 2011/04/21 06:00
MHDA- 2012/01/06 06:00
CRDT- 2011/04/21 06:00
PHST- 2011/04/21 06:00 [entrez]
PHST- 2011/04/21 06:00 [pubmed]
PHST- 2012/01/06 06:00 [medline]
AID - 1940-6207.CAPR-11-0083 [pii]
AID - 10.1158/1940-6207.CAPR-11-0083 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2011 Aug;4(8):1285-95. doi: 
      10.1158/1940-6207.CAPR-11-0083. Epub 2011 Apr 19.